HEAD-TO-HEAD

TRI-RECEPTOR INCRETIN AGONIST VS GLP-1 / GIP DUAL AGONIST

Both are next-generation incretin agonists from the originator pharma sponsor. the GLP-1/GIP dual agonist is the dual GLP-1R + GIPR agonist already FDA-approved as an FDA-approved class member (T2D) and the FDA-approved class member (weight management). the tri-receptor incretin agonist adds glucagon-receptor (GCGR) agonism as a third arm · investigational, currently in Phase 3 TRIUMPH. Phase 2 the tri-receptor incretin agonist showed deeper body-weight reduction than published the GLP-1/GIP dual agonist data at comparable timepoints.

A · No. 001

TRI-RECEPTOR INCRETIN AGONIST

GLP-1 / GIP / Glucagon · investigational class

B · No. 002

GLP-1 / GIP DUAL AGONIST

Combined incretin receptor activation

SIDE BY SIDE

FIELD

A · TRI-RECEPTOR INCRETIN AGONIST

B · GLP-1 / GIP DUAL AGONIST

Class

Triple GLP-1R + GIPR + GCGR agonist

Dual GLP-1R + GIPR agonist

Development code

internal development code

LY3298176

Half-life

~6 days

~5 days

Route

Subcutaneous (weekly)

Best published Phase 2/3 outcome

-24.2% LS mean BW at 48 wk (12 mg arm, Jastreboff 2023)

-22.5% BW at 72 wk (SURMOUNT-1, 15 mg)

FDA status

Investigational · Phase 3 TRIUMPH ongoing

FDA-approved (the FDA-approved class member 2022, the FDA-approved class member 2023)

WADA status

Not listed (2026)

WHICH IS BETTER · BY GOAL

▶ Maximum body-weight reduction (preclinical)A · TRI-RECEPTOR INCRETIN AGONIST

Phase 2 the tri-receptor incretin agonist outperformed published the GLP-1/GIP dual agonist data at equivalent timepoints. The glucagon-receptor arm adds thermogenic / energy-expenditure component on top of incretin effects.

▶ Validated human-prescription pathwayB · GLP-1 / GIP DUAL AGONIST

the GLP-1/GIP dual agonist is FDA-approved with millions of prescriptions and a documented safety profile. the tri-receptor incretin agonist is investigational.

▶ Glycemic control (T2D)B · GLP-1 / GIP DUAL AGONIST

the GLP-1/GIP dual agonist has the SURPASS Phase 3 program and head-to-head data vs the long-acting GLP-1 agonist. the tri-receptor incretin agonist Phase 3 metabolic outcomes pending.

▶ Long-term safety recordB · GLP-1 / GIP DUAL AGONIST

the GLP-1/GIP dual agonist has years of post-marketing surveillance. the tri-receptor incretin agonist does not yet.

STACKING NOTE

Combining multiple incretin agonists is not supported by published research. They engage overlapping pathways and combined use is unstudied. Buyers researching the incretin category typically order both for in-vitro characterization, not simultaneous use.

SOURCED FROM GIGACOMPOUNDS

Both compounds are available as research-grade material at GigaCompounds · ≥99% purity · per-batch CoA. For laboratory research use only.

SOURCE AT GIGACOMPOUNDS ▶